Financial calendar 2008

Announcement no. 02, 2008


March 11, 2008:	Annual report from 01.01.2007 to 31.12.2007

March 28, 2008:	Shareholders meeting

May 28, 2008:	Interim report - 3 months

August 28, 2008:	Interim report - 6 months

November 26, 2008:	Interim report - 9 months


Further information:
Christina Tønnesen, Investor Relations	
Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com



About BioPorto:

BioPorto develops and markets antibodies and antibody-based products, including
tests to diagnose human disease, both for the benefit of individual patients
and to promote efficiency in the health sector. The Company's developments
include a test (NGAL) to diagnose and monitor acute kidney damage. 

BioPorto's strategy is to develop new methods based on its antibody portfolio
that can be patented and achieve a wide use in the diagnosis of various
diseases. 

BioPorto was founded in 2000 and has about 25 employees. The Company's B shares
are listed on OMX Nordic Exchange Copenhagen (symbol: BIOP B). BioPorto is
owned by a group of shareholders, none of whom owns more than 5%.
www.bioporto.com